Laura Ivete Rudaks

Dr. Laura Ivete Rudaks

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2024 in The Cerebellum
Verified
Journal Article
Open access
PDF file
LRLaura Ivete Rudaks
Laura Ivete Rudaks
DYDennis Yeow
Dennis Yeow
KNKarl Ng
Karl Ng
IDIra W. Deveson
Ira W. Deveson
MKMarina L. Kennerson
Marina L. Kennerson
KKKishore Raj Kumar
Kishore Raj Kumar
The hereditary cerebellar ataxias (HCAs) are rare, progressive neurologic disorders caused by variants in many different genes. Inheritance may follow autosomal dominant, autosomal recessive, X-linked or mitochondrial patterns. The list of genes associated with adult-onset cerebellar ataxia is continuously growing, with several new genes discovered in the last few years. This includes short-tandem repeat (STR) expansions in RFC1, causing cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS), FGF14-GAA causing spinocerebellar ataxia type 27B (SCA27B), and THAP11. In addition, the genetic basis for SCA4, has recently been identified as a STR expansion in ZFHX3. Given the large and growing number of genes, and different gene variant types, the approach to diagnostic testing for adult-onset HCA can be complex. Testing methods include targeted evaluation of STR expansions (e.g. SCAs, Friedreich ataxia, fragile X-associated tremor/ataxia syndrome, dentatorubral-pallidoluysian atrophy), next generation sequencing for conventional variants, which may include targeted gene panels, whole exome, or whole genome sequencing, followed by various potential additional tests. This review proposes a diagnostic approach for clinical testing, highlights the challenges with current testing technologies, and discusses future advances which may overcome these limitations. Implementing long-read sequencing has the potential to transform the diagnostic approach in HCA, with the overall aim to improve the diagnostic yield.

7 November 2011 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
LRLaura Ivete Rudaks
Laura Ivete Rudaks
JNJillian K. Nicholl
Jillian K. Nicholl
DBDrago Bratkovic
Drago Bratkovic
CBChristopher P. Barnett
Christopher P. Barnett
Laura I. Rudaks, Jillian K. Nicholl, Drago Bratkovic, and Christopher P. Barnet

3 September 2023 in Genes
Verified
Journal Article
Open access
PDF file
SSSue Faye Siow
Sue Faye Siow
DYDennis Yeow
Dennis Yeow
LRLaura Ivete Rudaks
Laura Ivete Rudaks
FJFangzhi Jia
Fangzhi Jia
GWGautam Wali
Gautam Wali
KKKishore Raj Kumar
Kishore Raj Kumar
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity. There is no disease-modifying treatment currently available. Therefore, standardized, validated outcome measures to facilitate clinical trials are urgently needed. We performed a scoping review of outcome measures and biomarkers for HSP to provide recommendations for future studies and identify areas for further research. We searched Embase, Medline, Scopus, Web of Science, and the Central Cochrane database. Seventy studies met the inclusion criteria, and eighty-three outcome measures were identified. The Spastic Paraplegia Rating Scale (SPRS) was the most widely used (27 studies), followed by the modified Ashworth Scale (18 studies) and magnetic resonance imaging (17 studies). Patient-reported outcome measures (PROMs) were infrequently used to assess treatment outcomes (28% of interventional studies). Diffusion tensor imaging, gait analysis and neurofilament light chain levels were the most promising biomarkers in terms of being able to differentiate patients from controls and correlate with clinical disease severity. Overall, we found variability and inconsistencies in use of outcome measures with a paucity of longitudinal data. We highlight the need for (1) a standardized set of core outcome measures, (2) validation of existing biomarkers, and (3) inclusion of PROMs in HSP clinical trials.

8 January 2024 in Tremor and Other Hyperkinetic Movements
Verified
Journal Article
Open access
PDF file
DYDennis Yeow
Dennis Yeow
LRLaura Ivete Rudaks
Laura Ivete Rudaks
SSSue Faye Siow
Sue Faye Siow
RDRyan L. Davis
Ryan L. Davis
KKKishore Raj Kumar
Kishore Raj Kumar
Currently, pathogenic variants in more than 500 different genes are known to cause various movement disorders. The increasing accessibility and reducing cost of genetic testing has resulted in increasing clinical use of genetic testing for the diagnosis of movement disorders. However, the optimal use case(s) for genetic testing at a patient level remain ill-defined. Here, we review the utility of genetic testing in patients with movement disorders and also highlight current challenges and limitations that need to be considered when making decisions about genetic testing in clinical practice. Highlights The utility of genetic testing extends across multiple clinical and non-clinical domains. Here we review different aspects of the utility of genetic testing for movement disorders and the numerous associated challenges and limitations. These factors should be weighed on a case-by-case basis when requesting genetic tests in clinical practice.

14 May 2024 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
AFAvi Fellner
Avi Fellner
GWGurusidheshwar M. Wali
Gurusidheshwar M. Wali
NMNeil Mahant
Neil Mahant
BGBianca R. Grosz
Bianca R. Grosz
MEMelina Ellis
Melina Ellis
KKKishore Raj Kumar
Kishore Raj Kumar
We investigated the contribution of genomic data reanalysis to the diagnostic yield of dystonia patients who remained undiagnosed after prior genome sequencing. Probands with heterogeneous dystonia phenotypes who underwent initial genome sequencing (GS) analysis in 2019 were included in the reanalysis, which was performed through gene-specific discovery collaborations and systematic genomic data reanalysis. Initial GS analysis in 2019 (n = 111) identified a molecular diagnosis in 11.7 % (13/111) of cases. Reanalysis between 2020 and 2023 increased the diagnostic yield by 7.2 % (8/111); 3.6 % (4/111) through focused gene-specific clinical correlation collaborative efforts [VPS16 (two probands), AOPEP and POLG], and 3.6 % (4/111) by systematic reanalysis completed in 2023 [NUS1 (two probands) and DDX3X variants, and a microdeletion encompassing VPS16]. Seven of these patients had a high phenotype-based dystonia score ≥3. Notable unverified findings in four additional cases included suspicious variants of uncertain significance in FBXL4 and EIF2AK2, and potential phenotypic expansion associated with SLC2A1 and TREX1 variants. GS data reanalysis increased the diagnostic yield from 11.7 % to 18.9 %, with potential extension up to 22.5 %. While optimal timing for diagnostic reanalysis remains to be determined, this study demonstrates that periodic re-interrogation of dystonia GS datasets can provide additional genetic diagnoses, which may have significant implications for patients and their families.

1 June 2012 in Pediatric Neurology
Verified
Journal Article
Closed access
LRLaura Ivete Rudaks
Laura Ivete Rudaks
SPSandeep Patel
Sandeep Patel
CBChristopher P. Barnett
Christopher P. Barnett